Play

Another monoclonal antibody against Covid-19 has been developed and appears to work in reducing severe disease and hospitalization. This one is unique, however, according to Brian Garibaldi, a critical care medicine expert at Johns Hopkins. Garibaldi: The interesting thing about …

Do we really need a new monoclonal antibody for Covid-19? Elizabeth Tracey reports Read more »

Play

Monoclonal antibodies remain a treatment option for those in early stages of Covid infection, even in the face of new oral medications that likely will be available soon. Brian Garibaldi, a critical care medicine expert at Johns Hopkins, says the …

If you’ve been exposed to Covid-19, should you have monoclonal antibody treatment? Elizabeth Tracey reports Read more »

Play

Both Pfizer and Merck have recently revealed promising data on oral medicines for early Covid-19 infection, with both companies on the threshold of widespread use of the drugs. Brian Garibaldi, a critical care medicine expert at Johns Hopkins, says he …

Two new oral medicines for Covid-19 are poised for widespread use, Elizabeth Tracey reports Read more »

Play

Pfizer has asked the FDA to approve its new oral medication for Covid-19, called Paxlovid, for people in the early stages of infection. Brian Garibaldi, a critical care medicine expert at Johns Hopkins, reviews the data. Garibaldi: From symptom onset …

What do we know about the new oral medicine from Pfizer for Covid? Elizabeth Tracey reports Read more »

Play

More expensive analog insulins are used by the majority of people with diabetes who use insulin, a study by Rita Kalyani, a diabetes expert at Johns Hopkins, and colleagues has shown. Is this practice based in any professional society recommendations? …

What are the recommendations regarding the best insulin to manage diabetes? Elizabeth Tracey reports Read more »

Play

When someone is taking insulin for diabetes, it’s important to monitor and manage its use, but during the pandemic, that didn’t happen. That’s according to research by Rita Kalyani, a diabetes expert at Johns Hopkins, and colleagues. Kalyani: We saw …

What happened to close management of diabetes requiring insulin during the pandemic? Elizabeth Tracey reports Read more »

Play

Insulin costs have been cited as a case in point for out of control pharmaceutical prices. Now a study by Rita Kalyani, a diabetes expert at Johns Hopkins, and colleagues, shows that in fact, a survey of insulin use over …

How has use of insulin changed over the last five years in people with diabetes? Elizabeth Tracey reports Read more »